Relay Therapeutics' Triple Potential
This is a RLAY news story, published by Yahoo Finance, that relates primarily to Russell news.
RLAY news
For more RLAY news, you can click here:
more RLAY newsRussell news
For more Russell news, you can click here:
more Russell newsstocks trading & speculation news
For more stocks trading & speculation news, you can click here:
more stocks trading & speculation newsYahoo Finance news
For more news from Yahoo Finance, you can click here:
more news from Yahoo FinanceAbout the Otherweb
Otherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best business news, entertainment news, world news, and much more. If you like stocks trading & speculation news, you might also like this article about
cap stocks. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest broader market challenges news, global market drops news, stocks trading & speculation news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
other stocksInsider Trading & Hedge Fund Data, and Investment Newsletter From Insider Monkey
•Business
Business & Economics
Relay Therapeutics, Inc. (RLAY): Among Stocks Under $10 that Will Triple
84% Informative
The Russell index (which tracks small-cap stocks) has fallen over 15% from its peak in November 2024 as of the time of writing this article.
However, the broader market has only dropped about 14% on a YTD basis.
Small-cap companies with international supply chains now face higher costs that could damage their profitability.
The Federal Reserve’s decision to slow rate hikes in late 2024 provided some breathing room.
For FY24, Relay Therapeutics, Inc. (NASDAQ:RLAY) brought in $10 million in revenue, down from $25.5 million in 2023 .
The company ended Q4 with $781.3 million in cash and investments, a substantial reserve to continue with the ongoing clinical trials.
RLAY ranks 3rd on our list of stocks under $ 10 that will triple.
VR Score
89
Informative language
90
Neutral language
37
Article tone
semi-formal
Language
English
Language complexity
49
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
medium-lived
External references
6
Source diversity
1
Affiliate links
no affiliate links
Small business owner?